Is the price fair?
What SCL's price assumes
Stepan Company did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 0.48× revenue.
0.48
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 3.0%
Free cash flow yield · Specialty Chemicals median 3.9%
- Growth the price implies
- +12%
Growth the price implies · The price pays for +12% free cash flow growth a year for a decade; revenue has grown −5.2% a year over the last three.
- Price / book
- 0.95
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 0.95
- EV / EBIToperating margin 0.03%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 0.70
- Free cash flow, trailing twelve months
- $37M
- Market capitalisation
- $1.23B
- 3-year revenue growth
- −5.2%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Specialty Chemicals
Ranks #27 of 36 by Smart Score